Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MDM2 | Q00987 | 11/20 | 0.36 |
| ▸ | CDK1 | P06493 | 2/20 | 0.36 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6095478 | 1.00 | ADORA1 (0.41) | ADORA1KDM4EMEN1MAPTKMT2A | |
| SCHEMBL6092521 | 0.80 | MDM2 (0.46) | ADORA1KDM4EMEN1MAPTKMT2A | |
| SCHEMBL6092515 | 0.80 | MDM2 (0.46) | ADORA1KDM4EMEN1MAPTKMT2A | |
| SCHEMBL6095319 | 0.76 | KDM4E (0.39) | ADORA1KDM4EMEN1KMT2ATP53 | |
| SCHEMBL6095215 | 0.76 | MDM2 (0.47) | ADORA1MDM2 | |
| SCHEMBL6095207 | 0.76 | MDM2 (0.47) | ADORA1MDM2 | |
| SCHEMBL12165831 | 0.70 | MAPT (0.64) | ADORA1KDM4EMEN1MAPTKMT2A | |
| SCHEMBL14670527 | 0.68 | KDM4E (0.50) | ADORA1KDM4EMEN1MAPTKMT2A | |
| SCHEMBL8592661 | 0.67 | ADORA1 (0.49) | ADORA1KDM4EMEN1MAPTKMT2A | |
| SCHEMBL8592666 | 0.67 | ADORA1 (0.49) | ADORA1KDM4EMEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7005430-B2 | Fused purine derivatives | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-02-28 | — | — | US | disclosed |
| EP-1251130-B1 | FUSED PURINE DERIVATIVES | KYOWA HAKKO KOGYO KK (JP) | 2005-02-16 | — | — | EP | disclosed |
| US-20030176698-A1 | Fused purine derivatives | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2003-09-18 | — | — | US | disclosed |
| EP-1251130-A1 | FUSED PURINE DERIVATIVES | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2002-10-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176698-A1 | Fused purine derivatives | PNP, NSUN2, CYP2W1 | ADORA1 64/4885KDM4E 2971/4885MEN1 4565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.